Skip to main content

Table 5 Studies describing hospital length of stay in patients with resistant and multidrug-resistant Pseudomonas aeruginosa infections

From: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author Study groups (n) Median (mean) Hospital Length of Stay (days) Reported Significance (p-value or 95% CI) Ref
Main findings
Brooklyn Antibiotic Resistance Task Force (2002)* Carbapenem susceptible P. aeruginosa (10) 20 (17) 0.002 (0.001) [60]
Carbapenem resistant P. aeruginosa (10) 33.5 (36)
Eagye et al. (2009)* Meropenem resistant P. aeruginosa (58) 30 <0.001 [53]
Meropenem susceptible P. aeruginosa (125) 16
Meropenem resistant P. aeruginosa (58) 30 <0.001
Control (57) 10
Evans et al. (2007) Susceptible P. aeruginosa (73) 20 0.03 [71]
Resistant P. aeruginosae (47) 26
Furtado et al. (2009) Imipenem resistant P. aeruginosa (63) 25 0.006 [62]
Control (182) 15
Gasink et al. (2006)* Fluoroquinolone resistant P. aeruginosa (320) 10 0.13 [64]
Fluoroquinolone susceptible P. aeruginosa (527) 9
Kaminski et al. (2011) Ureido/carboxypenicillin resistant P. aeruginosa (70) 50 0.24 [66]
Ureido/carboxypenicillin susceptible P. aeruginosa (153) 47.5
Lautenbach et al. (2010) Imipenem resistant P. aeruginosa (253) 16 <0.001 [63]
Imipenem susceptible P. aeruginosa (2289) 9
Morales et al. (2012) MDR P. aeruginosaf (134) 39 (45.7) <0.001a [49]
Susceptible P. aeruginosa (149) 20 (25.1)
Resistant P. aeruginosa (119) 30 (39.0) <0.001a
Susceptible P. aeruginosa (149) 20 (25.1)
Paramythiotou et al. (2004) MDR P. aeruginosag (34) 44.5 (57.0)b,d/11.1c,d 0.28/0.81 [54]
Control (34) 43.5 (46.9)b,d/5.8c,d
Tam et al. (2010) MDR P. aeruginosah (25) 26.4c 0.12 [13]
Susceptible P. aeruginosa (84) 16.5c
  1. *Length of stay reported after identification of infection with P. aeruginosa;Length of stay reported as total length of stay; Length of stay not defined as total length of stay or length of stay after identification of infection with P. aeruginosa; a P-value reported for mean length of stay; b Length of ICU stay (ICU stay matched between cases and controls); cLength of stay in hospital following ICU discharge; dStudy reported mean length of stay; eAbsence of susceptibility to all the drugs in one or more of the following antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; fAbsence of susceptibility to carbapenems, β-lactams, quinolones, tobramycin, and gentamicin; g Absence of susceptibility to piperacillin, ceftazidime, imipenem, and ciprofloxacin; hAbsence of susceptibility to three or more of the following four classes of agents: antipseudomonal carbapenems, antipseudomonal β-lactams (penicillins and cephalosporins), aminoglycosides, and fluoroquinolones.